title: Hyperthermic isolated liver perfusion with melphalan and bevacizumab.
abstract: Whereas surgical resection is the only curative treatment for liver tumors, effective treatment for isolated unresectable lesions when there is tumor progression in spite of several lines of chemotherapy remains to be found. We report herein two cases of patients treated by a 1-hour Hyperthermic Isolated Liver Perfusion (HILP) with a combination of melphalan and bevacizumab leading to complete response. The first patient had liver metastases secondary to previously resected malignant glucagonoma and the second, recurrent hepatocellular carcinoma. We used bevacizumab in association with melphalan for HILP because of the additional effect of an anti-VEGF antibody in these highly vascularized tumors and its locally restricted delivery to the isolated hepatic vascular compartment despite of its classic contraindication in association with surgery. The protocol was approved by the Ethics Committee. Enhanced CT scans during follow-up showed complete tumor necrosis as early as the second postoperative day. Patients had 27 and 7 months disease-free survival and 48 and 41 months overall survival after HILP, for neuroendocrine liver metastases and HILP plus liver transplantation for HCC respectively. Under very specific conditions, bevacizumab in HILP can provide excellent tumor response in hopeless clinical cases of liver tumors.
authors.affiliation: Service de chirurgie générale, digestive et oncologique, Inserm CIE4, hôpital Européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France.
authors.forename: T
authors.initials: T
authors.lastname: Voron
authors.forename: F
authors.initials: F
authors.lastname: Zinzindohoué
authors.forename: D
authors.initials: D
authors.lastname: Journois
authors.forename: C
authors.initials: C
authors.lastname: Hervé
authors.forename: O
authors.initials: O
authors.lastname: Ponzio
authors.forename: N
authors.initials: N
authors.lastname: Lucas
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D005935:Glucagonoma / Q000556:secondary / Q000628:therapy; D006801:Humans; D006979:Hyperthermia, Induced; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D008558:Melphalan